GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » Financial Strength

Accolade (Accolade) Financial Strength : 5 (As of Nov. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Accolade Financial Strength?

Accolade has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Accolade's interest coverage with the available data. Accolade's debt to revenue ratio for the quarter that ended in Nov. 2023 was 0.61. As of today, Accolade's Altman Z-Score is -0.43.


Competitive Comparison of Accolade's Financial Strength

For the Health Information Services subindustry, Accolade's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's Financial Strength Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's Financial Strength distribution charts can be found below:

* The bar in red indicates where Accolade's Financial Strength falls into.



Accolade Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Accolade's Interest Expense for the months ended in Nov. 2023 was $0.0 Mil. Its Operating Income for the months ended in Nov. 2023 was $-31.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was $234.8 Mil.

Accolade's Interest Coverage for the quarter that ended in Nov. 2023 is

GuruFocus does not calculate Accolade's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Accolade's Debt to Revenue Ratio for the quarter that ended in Nov. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Nov. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.9 + 234.798) / 397.484
=0.61

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Accolade has a Z-score of -0.43, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -0.43 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accolade  (NAS:ACCD) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Accolade has the Financial Strength Rank of 5.


Accolade Financial Strength Related Terms

Thank you for viewing the detailed overview of Accolade's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111